Imaging study for HER2-positive cancers using TGW211
Part of Cancer clinical trials.
This trial tests whether a new imaging agent called TGW211 can help doctors see HER2-positive cancers more clearly on scans. It may lead to better ways to track these cancers in the future.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a confirmed HER2-positive cancer with at least one tumor that can be seen on a CT or MRI scan.
- You are able to care for yourself and perform daily activities (ECOG score 0 or 1).
- Your blood tests show your organs and bone marrow are working well enough.
- You do not have serious heart, lung, or other health conditions that could interfere with the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an imaging technique that uses a special tracer to attach to HER2 (a protein on some cancer cells) and make it visible on a PET/CT scan. The goal is to see if the tracer can help doctors understand where HER2 is in the body, which may guide future treatment options for advanced lung cancer.
This trial tests a new imaging agent called [68Ga]Ga-DWJ155 to see how well it helps detect certain types of advanced breast cancer and non-small cell lung cancer. It may help doctors better understand the cancer and guide treatment decisions.
This study uses a radioactive tracer to see how much HER2 protein is on your breast cancer cells. The scan may help doctors understand the type of HER2 you have and choose the best treatment.
This study tests a new PET scan tracer to show where HER2-positive breast cancer cells may be in the body. It may help doctors better “map” HER2 activity, including in people with HER2-positive or HER2-negative cancer.
This study uses a radioactive tracer to take pictures of tumors that have a protein called HER2. It may help doctors see where the cancer is in your body and could guide future treatment decisions.
This trial tests a new imaging method that uses a radioactive tracer to find HER2-positive cancer cells in the body. It may help doctors see tumors more clearly in people with stomach, breast, or bladder cancer.
Hear when a new HER2 Positive Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.